title: Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
abstract: The need for novel antihypertensive therapies represents a continuous challenge. LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor that has been shown to enhance endogenous natriuretic peptide (NP) actions on neurohormonal activation. This effect seems to be additive to that of the renin-angiotensin-aldosterone system (RAAS) suppression, as impressively suggested in the PARADIGM HF study. LCZ696 has been shown to be effective in reducing blood pressure in several small studies; however, its effectiveness and safety remain to be proved in larger studies. This review summarizes the role of RAAS and NP system in the pathophysiology of hypertension and reviews the current data on the antihypertensive effects of LCZ696.
authors.affiliation: Cardiology Department, Hippokration Hospital, Athens, Greece.
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Katsi
authors.affiliation: Department of Cardiology, Helena Venizelou Hospital, Athens, Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Skalis
authors.affiliation: Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, SE1 7EH London, UK antonispav@yahoo.com.
authors.forename: Antonis N
authors.initials: AN
authors.lastname: Pavlidis
authors.affiliation: Department of Cardiology, Helena Venizelou Hospital, Athens, Greece.
authors.forename: Thomas
authors.initials: T
authors.lastname: Makris
authors.affiliation: 1st Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Petros
authors.initials: P
authors.lastname: Nihoyannopoulos
authors.affiliation: 1st Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Dimitris
authors.initials: D
authors.lastname: Tousoulis
authors.affiliation: Cardiology Department, Hippokration Hospital, Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kallikazaros
mesh_terms: D000613:Aminobutyrates / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D001713:Biphenyl Compounds; D001794:Blood Pressure / Q000187:drug effects*; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D015260:Neprilysin; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: Aortic stiffness; Hypertension; LCZ696; Natriuretic peptides; Neprilysin